Rovin Capital’s Bristol-Myers Squibb BMY Stock Holding History

Rovin Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$987K	Buy	18,294 +7,672	+72%	+$369K	0.26%	72
2025 Q3	$479K	Buy	10,622 +1,096	+12%	+$51.2K	0.13%	121
2025 Q2	$441K	Sell	9,526 -1,418	-13%	-$69.6K	0.13%	124
2025 Q1	$667K	Sell	10,944 -3,372	-24%	-$197K	0.21%	78
2024 Q4	$810K	Sell	14,316 -2,810	-16%	-$157K	0.29%	62
2024 Q3	$886K	Buy	17,126 +4,256	+33%	+$200K	0.33%	62
2024 Q2	$534K	Buy	12,870 +7,546	+142%	+$338K	0.22%	91
2024 Q1	$289K	Buy	+5,324	New	+$271K	0.12%	124
2023 Q2	–	Sell	-2,945	Closed	-$204K	–	133
2023 Q1	$204K	Sell	2,945 -17	-0.6%	-$1.2K	0.1%	125
2022 Q4	$213K	Sell	2,962 -46	-2%	-$3.47K	0.11%	118
2022 Q3	$214K	Sell	3,008 -109	-3%	-$7.91K	0.12%	110
2022 Q2	$240K	Sell	3,117 -4,513	-59%	-$344K	0.16%	100
2022 Q1	$557K	Sell	7,630 -3,905	-34%	-$262K	0.3%	57
2021 Q4	$719K	Buy	+11,535	New	+$677K	0.35%	41

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Rovin Capital's BMY Position: Q4 2025 in Review

Rovin Capital increased its Bristol-Myers Squibb (BMY) stake by 72% in Q4 2025, buying an estimated $369K and bringing the position to 18,294 shares worth $987K. The position accounts for 0.26% of the portfolio, ranked #72.

Rovin Capital first reported a position in BMY in Q4 2021 and has held it in 14 quarters since. 2,447 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

Rovin Capital held 18,294 shares of Bristol-Myers Squibb worth $987K as of Q4 2025.
Rovin Capital bought 7,672 Bristol-Myers Squibb shares in Q4 2025, an estimated $369K.
Bristol-Myers Squibb made up 0.26% of Rovin Capital's portfolio in Q4 2025, its #72 holding.
Rovin Capital first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 14 quarters since.
2,447 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Rovin Capital's 13F filing for Q4 2025, filed 9 Feb 2026.